Search
Flotufolastat F-18
go.drugbank.com/drugs/DB17851ApprovedInvestigational[A259846] In May 2023, the FDA approved the use of flotufolastat F-18 for PET of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive … therapy or suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
Acetazolamide
go.drugbank.com/drugs/DB00819ApprovedInvestigationalVet approvedIt is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual … Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition
Synonyms: N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide, N-[5-(aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamideEtuvetidigene Autotemcel
go.drugbank.com/drugs/DB17593ApprovedInvestigationalEtuvetidigene autotemcel is an autologous gene therapy which includes hematopoietic stem cells (HSCs) that have been genetically modified ex vivo. … [A274878] The WAS protein is expressed on non-erythroid hematopoietic cells and regulates the function of actin filaments in the cytoskeleton.[A274878]
Pyridoxal phosphate
go.drugbank.com/drugs/DB00114ApprovedInvestigationalNutraceuticalThis is the active form of vitamin B6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is tra...
Mixtures: EnlSodium tartrate
go.drugbank.com/drugs/DB13707ApprovedWithdrawnIt acts as an emulsifier and pH control agent in food products [L2590]. … This compound is commonly used as an emulsifier in cheese/cheese spread products and is not to exceed 4% concentration, according to Health Canada regulations [L2594].
Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalThe treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. … Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC).
Ozanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigationalin MS therapy. … [L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020.
Amiloride
go.drugbank.com/drugs/DB00594ApprovedInvestigationalAmiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705) … This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct.
Synonyms: N-amidino-3,5-diamino-6-chloropyrazinecarboxamide, 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamideMigalastat
go.drugbank.com/drugs/DB05018ApprovedInvestigationalThis enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and other … [L47036,L47057,L4274,L4278] In the U.S., it is estimated that more than 3,000 people are living with Fabry disease, and an estimated more than 50 percent of these diagnosed patients are currently untreated
Penpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigationalThe use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events. … [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998]